Can-Fite Biopharma Ltd (CANF) Stock Price & How to Invest

Can-Fite BioPharma Ltd. is an Israeli clinical-stage biopharmaceutical company that trades in the US as an ADR on the NYSE American. Its platform is built on the A3 adenosine receptor (A3AR), a G-protein-coupled receptor that is highly expressed on inflammatory and cancer cells but has low expression in normal cells, which the company argues makes it a selective drug target across cancer, liver disease, and inflammatory conditions. Can-Fite has no approved products and generates essentially no product revenue; it is a research-and-development-stage business whose value rests entirely on its pipeline of small-molecule A3AR drug candidates and its ability to fund years of clinical trials. Its two lead candidates are Namodenoson, in Phase 3 for advanced liver cancer (hepatocellular carcinoma) with additional studies in MASH (a metabolic liver disease) and pancreatic cancer, and Piclidenoson, in a pivotal Phase 3 study for psoriasis.

The financial profile reflects the risks of a very small clinical-stage company. Can-Fite reported net losses of roughly $9.8 million in 2025 (versus about $7.9 million in 2024) and an accumulated deficit of around $176 million as of December 31, 2025, with cash and equivalents of about $5.5 million plus short-term deposits near $3.0 million at that date; management stated this was expected to fund operations for roughly twelve months, meaning additional capital will be needed after that. The company has repeatedly relied on dilutive equity financing (including a roughly $4.3 million raise in early 2026) and, in January 2026, carried out a 1-for-3,000 reverse split of its ordinary shares with an ADS ratio change (broadly equivalent to a 1-for-20 reverse ADS split) to maintain exchange-listing compliance, a move that typically signals significant liquidity and share-price pressure. Clinical readouts expected around and beyond late 2026 (including Phase 3 liver-cancer data and a Piclidenoson psoriasis interim analysis) are the key events that could sharply move the stock in either direction.

This is a highly speculative micro-cap with concentrated, binary risk. The dominant risk is clinical failure: Can-Fite has no approved products, and negative or delayed results from the Namodenoson liver-cancer Phase 3 or the Piclidenoson psoriasis study could sharply and permanently reduce the value of the shares. Financing and dilution risk is severe: with only a few million dollars of cash and recurring annual losses, the company depends on repeated dilutive equity raises to continue operating, and the January 2026 1-for-3,000 reverse split (with ADS ratio change) reflects pressure to maintain NYSE American listing compliance, a pattern that can continue. Going-concern-type dependence on future funding means shareholders can be diluted heavily even when trials progress. Additional risks include regulatory uncertainty (FDA and other agencies may not accept the data), competition from far larger and better-capitalized drug developers, small size and thin trading that can make the ADR volatile and hard to exit, and the general reality that most clinical-stage drug candidates never reach approval. Investors should treat any position as speculative capital they can afford to lose.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Can-Fite Biopharma Ltd's investor relations page or your broker.

• Revenue / earnings: Pre-revenue clinical-stage company with no approved products; it reports recurring net losses, not profits
• Net loss (2025): approximately $9.8 million (versus about $7.9 million in 2024)
• Accumulated deficit: approximately $176 million as of December 31, 2025
• Cash position: approximately $5.5 million cash plus about $3.0 million short-term deposits at December 31, 2025; management indicated roughly twelve months of runway from that point, with more capital needed thereafter
• Pipeline stage: Namodenoson in Phase 3 (liver cancer) plus Phase 2 (MASH, pancreatic cancer); Piclidenoson in Phase 3 (psoriasis)
• Capital structure note: 1-for-3,000 reverse split of ordinary shares with ADS ratio change in January 2026 (broadly a 1-for-20 reverse ADS split); roughly $4.3 million dilutive raise in early 2026

Figures are approximate and tied to the asOf date; verify live numbers before acting. For a pre-revenue biotech, traditional valuation metrics such as P/E do not apply, because there are no earnings; what matters is cash runway, the probability and timing of clinical readouts, and dilution. The small cash balance, recurring losses, dependence on dilutive financing, and a large reverse split all point to significant liquidity pressure, so the investment case is a speculative, binary bet on trial outcomes rather than on any current financial performance.

There are three common ways to get CANF exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so CANF sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where CANF fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Can-Fite is a micro-cap, clinical-stage biotech with no approved products, running on a small cash balance and dependent on dilutive financing. It is a speculative, binary bet on A3AR drug-candidate trial results (Namodenoson and Piclidenoson), where outcomes and funding, not earnings, drive the stock. Suitable only for risk-tolerant, speculative capital.